OR WAIT null SECS
March 21, 2023
Sanofi intends to cut its US list price for Lantus (insulin glargine injection) by 78% and cap out-of-pocket costs at $35 for all patients with commercial insurance.
BioNTech will receive an exclusive worldwide license from OncoC4 to develop and commercialize its anti-CTLA-4 mAb candidate for solid tumor indications.
March 17, 2023
Stevanato Group will support development and production of pre-fillable syringes for use in Recipharm’s soft mist inhalers.
Evotec and Bristol Myers Squibb have announced progress in their strategic protein degradation partnership.
Predictive Oncology and Cancer Research Horizons have partnered to pursue development of cancer drugs utilizing the PEDAL platform.
The collaboration between Genuv and Celltrion will utilize Genuv's proprietary mouse platform for antibody discovery.
March 16, 2023
Pfizer will acquire all outstanding shares of Seagen for a total of $43 billion.
March 15, 2023
The impact of the potential ban would have serious consequences for the availability of many drugs for European patients.
March 14, 2023
FDA has approved Acadia Pharmaceuticlas’ Daybue (trofinetide), the first treatment for Rett syndrome, a rare genetic disorder.
FDA has approved Pfizer’s ZAVZPRET (zavegepant), a new nasal spray treatment for migraine.